Navigation Links
Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point
Date:3/17/2010

CAMBRIDGE, Mass., March 17 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced the results of a new Sermo Category Report titled "Anticoagulant Therapies: Physicians Social Media Conversations." The report analyzes a full year of peer-to-peer conversations about blood clotting, anticoagulation, anti-platelet, and thrombolytic treatments. According to the findings, although physicians highly anticipate Xarelto (Bayer/ Johnson & Johnson), they have concerns about its safety and cost. Many physicians note that generics will likely benefit from an assumed price advantage even though the potential for Xarelto is high.

"Physicians constantly need to walk a fine line, weighing the risk of stroke against the risk of bleeding," said Dr. Adam Sharp, Chief Medical Officer at Sermo.  "If Xarelto can help balance these risks through an oral, non-monitored treatment, it has a lot of potential to encourage compliance and improve patient satisfaction.  Physicians on Sermo are optimistic to see if Xarelto can deliver on this promise, but still have questions about safety and cost."

Although speculation about Xarelto makes it standout among physician discussion about anticoagulants, risk management and existing treatment options drive much of the conversation.  The report closely examines which issues are discussed most frequently, how physicians feel about brands and therapies, and changes in physician perception about treatments over time.

Top companies and medications analyzed in this report include Coumadin (Bristol-Myers Squibb), Xarelto (Bayer/Johnson & Johnson), Plavix (Bristol-Myers Squibb/sanofi-aventis), Lovenox (sanofi-aventis), Effient (Eli Lilly), Heparin, and thrombolytics.

Thrombosis is the 5th most discussed medical condition within the Sermo community.  Leveraging Sermo's social media platform, the report analyzes more than 5,000 comments generated by 1,672 physicians from 2/09-1/10.  

Visit http://www.sermo.com/client/anticoagulants or call 877-778-3963 to learn more about this report.

About Sermo Category Reports:

Everyday, physicians on Sermo have discussions that shape their practices and prescribing behavior. Sermo Category Reports tap into these peer-peer conversations to provide valuable market intelligence not possible through other channels. Reports are in PowerPoint format and include full discussion analysis. Learn more.

About Sermo

Sermo is the largest online physician community in the US, where over 112,000 practicing physicians collaborate to improve patient care. Through a unique set of social media tools, Sermo provides access to its community for organizations that need fast, actionable MD insights into treatments, drugs and devices. Visit http://www.sermo.com or call client services at 877-778-3963 to learn more.  

SOURCE Sermo

Back to top

RELATED LINKS
http://www.sermo.com

'/>"/>

SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Physicians Reconsider Implications of Enhance Trial
6. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
7. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
8. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
9. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
10. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
11. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 , The data will be ... # 8006)   The conclusions of the study ... treated patients with 90% of the m presenting ... . Seventy two percent of the patients had clinical benefit. ... results from a Phase I study of plitidepsin in combination with bortezomib and ...
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
(Date:5/23/2016)... ... 2016 , ... During Logan University’s (Logan) Spring ... awarded $6,000 in chiropractic scholarships. The winners of the three $2,000 scholarships ... fifth trimester of classes at Logan. , “Standard Process has been extremely generous ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hospice of Westchester (HOW), ... for over 24 years, recently hosted its sixth annual Celebration of Life Memorial ... remembrance ceremonies, each concluding with the release of Monarch butterflies that honored the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... ... May 23, 2016 , ... While new ... epidemic (1), physicians are not legally required to follow them. In the absence ... 3, 4). Novus Medical Detox Center , a leading Florida-based drug treatment ...
Breaking Medicine News(10 mins):